双特异性抗体在抗人类免疫缺陷病毒方面的研究进展  

Research progress in bispecific antibodies against HIV

作　　者：刘广文 秦嘉萍 顾汇权 刘嫱[1] LIU Guangwen;QIN Jiaping;GU Huiquan;LIU Qiang(Department of Pharmacology,School of Basic Medicine and Life Sciences,Hainan Medical College,Haikou,Hainan 571199,China)

机构地区：[1]海南医学院基础医学与生命科学院药理教研室,海南海口571199

出　　处：《安徽医药》2023年第2期213-217,共5页Anhui Medical and Pharmaceutical Journal

基　　金：国家自然科学基金项目(82060851);海南省高校科学研究重点课题计划项目(Hnky2019ZD-26)。

摘　　要：双特异性抗体(bispecific antibody,BsAb)是一种工程化的非自然抗体。由于大多数单克隆抗体(monoclonal antibody,mAb)的抗病毒活性有限,而双特异性抗体通过结构的修饰,可以同时作用于病毒和宿主细胞不同的抗原表位,在免疫治疗中具有更高的特异性以及更大广度及效力,在抗人类免疫缺陷病毒(HIV)研究领域中双特异性抗体的研究已成为一大热点,现就抗HIV双特异性抗体的研究作一综述。Bispecific antibodies(bsAb)are engineered antibody.Due to the limited antiviral activity of most monoclonal antibodies(mAb),bispecific antibodies can act on different epitopes of the virus and host cells at the same time through structural modification,and have higher performance in immunotherapy specificity,greater breadth and effectiveness,and the research of bispecific antibodies in the field of anti-AIDS virus(HIV)research has become a hot topic.This article summarizes the research on anti-HIV bispecific antibodies.

关 键 词：获得性免疫缺陷综合征 人类免疫缺陷病毒抗体 双特异性抗体 单克隆抗体 人类免疫缺陷病毒 

分 类 号：R512.91[医药卫生—内科学]